A Phase I, Single-centre, 2-part, Open Study to assess the safety and tolerability of AZD2171 following singel and multiple oral doses in patients with solid malignant tumors and metastatic liver disease (in collaboration with Fa. AstraZeneca GmbH, Wedel).

A Phase I, Single-centre, 2-part, Open Study to assess the safety and tolerability of AZD2171 following singel and multiple oral doses in patients with solid malignant tumors and metastatic liver disease.

Ansprechpartner: Strecker R.
Tel: 0761-270-7412
Email: ralph.strecker@uniklinik-freiburg.de

Projektbeginn: 22.01.2003
Projektende: 31.12.2005

Hennig J.

Albert-Ludwigs-Universität Freiburg
Department für Radiologische Diagnostik und Therapie
Klinik für Radiologie
Hugstetterstrasse 55
79106 Freiburg

Telefon: +49-761-270-38050/38060
Fax: +49-761-270-38380

• AstraZeneca GmbH, Firma